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Summary
Background:  Cascade  and  restrictive  reporting  are  useful  strategies  to  enhance
antibiotic  stewardship  programs.
Methods:  We  combined  both  strategies  to  improve  the  prescribing  of  antibiotics
aimed  at  Gram-negative  infections.
Results:  For  Enterobacter  aerogenes, the  susceptibility  rates  to  amikacin  increasedresistance
from  10%  to  100%;  for  third  generation  cephalosporins,  these  rates  increased
from  55%  to  89%.  The  susceptibility  rates  of  E.  aerogenes  to  cefepime
and  piperacillin—tazobactam  changed  little,  and  the  ampicillin  susceptibility
decreased  from  30%  in  2009  to  11%  in  2010.  For  Proteus  mirabilis,  the  sus-
ceptibility  rates  increased  for  third-generation  cephalosporins  (48%  vs.  92%)
and  piperacillin—tazobactam  (10%  vs.  98%),  with  minimal  changes  for  cefepime
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he  inappropriate  use  of  antibiotics  has  societal
onsequences due  to  ecological  effects  on  both
atients  and  the  environment  [1,2].  These  conse-
uences  include  the  emergence  of  antimicrobial
esistance,  which  is  a  particularly  ominous  sign
n the  development  of  modern  healthcare.  Exam-
les of  this  resistance  include  several  pathogens,
uch as  Klebsiella  pneumoniae, Acinetobacter  bau-
annii, Pseudomonas  aeruginosa  and  Enterobacter
pecies, all  of  which  may  be  multi-drug  resistant
3,4].  Formulary  restriction  is  already  known  to
ead to  signiﬁcant  and  immediate  reductions  in
ntimicrobial  prescribing  and  cost  [5]. Controlling
ntibiotic consumption  impacts  the  resistance  rates
nd forms  the  main  basis  of  antimicrobial  steward-
hip  programs.  Additional  requirements  include  the
onitoring and  reporting  of  antibiotic  resistance
ollowing laboratory  characterization.  The  Clinical
nd Laboratory  Standards  Institute  (CLSI)  has  pub-
ished guidelines  for  the  analysis  and  presentation
f cumulative  antimicrobial  susceptibility  testing
6].  In  one  study,  the  use  of  a  clinical  syndrome-wise
ategorization  of  antimicrobial  agents  achieved
table susceptibility  of  nosocomial  isolates  [7].
dherence to  the  principles  of  antibiotic  use  and
ffective  monitoring  were  useful  in  halting  bacte-
ial resistance  [8].
The  selective  or  cascade  reporting  of  antimi-
robial susceptibilities  may  be  employed  in  an
ntimicrobial  stewardship  initiative  [9]. In  cascade
eporting,  antimicrobial  agents  of  each  class  are
anked based  on  a  spectrum  of  activity,  popular-
ty or  potential  for  the  over-prescribing  risk  of
rug resistance  and  cost.  Thus,  the  reported  antibi-
gram should  include  the  most  appropriate  and
east expensive  drugs,  provided  the  organism  is  sus-
eptible.  Higher  risk  agents  are  only  released  if
lternative  options  are  lacking.  In  selective  repor-
ing, the  susceptibilities  of  broad-spectrum  agents
nd those  drugs  at  risk  for  over-prescription  are
c
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69%  vs.  73%)  and  amikacin  (96%  vs.  84%).  For  Pseu-
sceptibility  rates  improved  slightly  for  third-generation
 but  reduced  for  piperacillin—tazobactam  (99%  vs.  59%).
m  difﬁcile  infections  decreased  from  0.11  to  0.07  per
ing  helps  physicians  choose  the  most  appropriate  antibi-
hin  a  stewardship  program,  with  reduced  C.  difﬁcile
ziz  University  for  Health  Sciences.  Published  by  Elsevier
eliberately  withheld  [5,9,10].  The  CLSI  guide-
ines specify  antibiotics  within  categories  that  must
e reported,  e.g.,  group  A  and  group  B, which
hould be  suppressed  [11].  Group  A  is  the  suggested
rouping of  antimicrobial  agents  with  FDA  clinical
ndications  that  should  be  considered  for  routine
esting and  reporting  on  non-fastidious  organisms
y clinical  microbiology  laboratories  in  the  United
tates.  Group  B  represents  the  suggested  grouping
f antimicrobial  agents  with  FDA  clinical  indica-
ions that  should  be  considered  for  routine  testing
nd reporting  on  fastidious  organisms  by  clini-
al microbiology  laboratories  in  the  United  States.
he ultimate  goal  is  to  reduce  antimicrobial  con-
umption,  particularly  the  use  of  broad-spectrum
gents, to  minimize  the  resistance  potential.  Selec-
ive reporting  helps  prescribers  choose  the  most
ppropriate  antimicrobial  agent  based  on  a sus-
eptibility  pattern.  Additional  strategies,  such  as
ntimicrobial  order  sheets,  automatic  stop  orders
nd therapeutic  substitution,  are  available  to  fur-
her enhance  the  best  use  of  antibiotics  [12]. We
xamined  the  effect  of  the  selective  reporting  of
elected broad-spectrum  agents  against  pathogens
ith high  resistance  rates  in  our  hospital.
aterials and methods
ospital setting and infection control
rogram
he  Saudi  Aramco  Medical  Services  Organization
SAMSO) provides  medical  care  for  approximately
70,000 patients.  The  main  hospital,  Dhahran
ealth Center  (DHC),  is  a 380-bed  general  hospi-
al with  ﬁve  intensive  care  units  (cardiac,  medical,
urgical,  pediatric  and  neonatal).  The  hospital
aters to  a wide  range  of  patients,  including  gen-
ral medicine  and  surgery,  intensive  care  and
he management  of  hematological  and  solid  organ
alignancies.  Over  36,000  patients  are  admitted
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every  year,  with  the  total  number  of  patient-days
being 193,725  (the  average  length  of  stay  was
5.3 days)  [13]. A  previous  study  in  this  hospital
between 2006  and  2008  showed  that  ciproﬂoxacin
was the  most  commonly  used  intravenous  antibiotic
(67.6%  of  total  parenteral  antibiotic  consumption),
followed by  ceftriaxone  (6%),  cefazolin  (5%)  and
imipenem-enzyme  inhibitor  (4.3%)  [14].  From  2006
to 2008,  the  annual  consumption  rates  of  intra-
venous antimicrobial  agents  in  deﬁned  daily  doses
(DDDs) per  100  patient-days  were  the  following:
ciproﬂoxacin  82.643,  ceftriaxone  7.447,  cefazolin
6.166,  imipenem-enzyme  inhibitor  5.234  and  levo-
ﬂoxacin  3.188  [14]. The  annual  incidence  rates
of Clostridium  difﬁcile  infection  in  our  hospi-
tal were  2.4  and  1.7  per  10,000  patient  days
in 2007  and  2008,  respectively  [15].  The  most
common organisms  causing  catheter-associated
bloodstream  infections  between  2002  and  2006
were  coagulase-negative  staphylococci  (23.7%),
Staphylococcus aureus  (11.1%),  Escherichia  coli
(11.1%),  candida  (5%),  K.  pneumoniae  (9%)  and  P.
aeruginosa (7.3%)  [16].  Nosocomial  Enterobacter
cloacae isolates  were  more  resistant  to  ceftriaxone
o
i
f
c
Figure  1  Original  and  modiﬁed  antibiotic  panels  for
marked  with  X  were  the  original  panels  that  were  m
lined  antibiotics  were  removed,  while  the  other  antibi
TOB  =  tobramycin;  C  =  chloramphenicol;  TE  =  tetracycline;  
Trimeth-Sulfa  =  trimethoprim—sulfamethoxazole.J.A.  Al-Tawﬁq  et  al.
17.5  vs.  5.5%),  ciproﬂoxacin  (9.5  vs.  4.7%)  and
icarcillin—clavulanic  acid  (23  vs.  9.3%)  than  out-
atient isolates  [17].
esign
n  May  2010,  Clinical  Laboratory  Services  and  Phar-
acy agreed  to  implement  the  selective  reporting
f tested  antibiotics  based  on  availability  within  the
ospital antibiotic  formulary.  Additional  antibiotics
ere tested  for  a cumulative  susceptibility  report
ut were  excluded  from  the  patient  report.  Repor-
ing was  also  modiﬁed  by  offering  antibiotics  that
an be  administered  at  least  two  different  ways,
.g., intravenous  and  oral  administration.
We speciﬁcally  targeted  Gram-negative  bacil-
us (GNB)  susceptibility  reporting  for  this  initiative
ecause  74%  of  all  organisms  isolated  in  our  lab-
ratory  are  GNB,  speciﬁcally,  Enterobacter  spp.,
roteus  spp.  and  P.  aeruginosa. Thus,  the  reporting
f Enterobacteriaceae  and  Pseudomonas  was  mod-
ﬁed, with  at  least  four  main  antibiotics  removed
rom the  panels  (Figs.  1 and  2).  The  reported  sus-
eptibility  pattern  was  pertinent  to  valid  clinical
 Enterobacteriaceae  for  patient  reporting.  Tables
erged  into  one  modiﬁed  panel  (middle).  Under-
otics  remained.  ATM  =  aztreonam;  CAZ  =  ceftazidime;
MZ  =  mezlocillin;  PIP  =  piperacillin;  CB  =  carbenicillin;
Restrictive  reporting  of  selected  antimicrobial  suscepti
Figure  2  Original  and  modiﬁed  antibiotic  reporting  pan-
els  for  Pseudomonas  aeruginosa. The  table  marked  X
is  the  original  reporting  panel.  Underlined  antibiotics
were  removed;  antibiotics  not  underlined  were  retained,
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antibiotic utilization  was  calculated  as  DDDs  andnd  antibiotics  in  italics  were  added.  ATM  =  aztreonam;
Z  =  mezlocillin;  PIP  =  piperacillin.
solates,  linked  with  septic  patients,  non-duplicate
nd from  hospitalized  patients.
Antibiotic  susceptibilities  were  chosen  for
elease after  considering  local  resistance  rates,
harmacokinetic  factors  and  recommendations
rom international  organizations,  e.g.,  the  Infec-
ious Disease  Society  of  America  (IDSA).  If  more
han 20%  of  isolates  were  resistant  to  a  speciﬁc
ntibiotic, this  agent  was  excluded  from  the  repor-
ing panel.  If  susceptibility  was  conﬁrmed,  having  a
esistance rate  >20%  did  not  preclude  reporting  the
usceptibility  result  for  that  antibiotic/organism
ombination  if clinically  indicated.  However,  if  the
revalence  of  resistance  was  >20%,  the  antibiotic  in
uestion should  not  be  given  as  an  empirical  ther-
py.
The temporary  freezing  of  selected  antibi-
tics with  high  resistance  rates  (>20%)  to  GNB,
uch as  amikacin,  ampicillin  and  third  generation
ephalosporins,  was  instituted  for  Enterobacteri-
ceae when  possible  for  most  of  the  cephalosporins
nd when  other  agents  were  available.  Broad-
pectrum antibiotics  known  to  have  decreased
usceptibility  among  local  coliforms  were  also
emoved  from  the  panel.  The  reporting  of  antibi-
tics within  the  same  class,  e.g.,  3rd  and  4th
eneration cephalosporins,  was  suppressed,  with
nly one  agent  released  in  the  report.  The
aboratory released  additional  antimicrobial  sus-
eptibilities  if the  patient  was  allergic  to  speciﬁed
ntimicrobial agents.  The  CLSI  2010  breakpoints
ere used,  and  Vitek  2  GNS-30  susceptibil-
ty cards  were  employed  for  MIC  values.  The
e
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reakpoints  remained  the  same  throughout  the
tudy.
We compared  the  antibiotic  utilization  as  DDDs
per 1000  patient-occupied  bed  days)  before  and
fter the  intervention.  We  also  compared  the
ntibiotic  susceptibilities  of  selected  organisms  (E.
erogenes; P. mirabilis;  P. aeruginosa) 6  months
efore  and  6  months  after  the  change  in  reporting.
No outbreaks  occurred  in  the  hospital  during
he study  period.  All  patients  with  multidrug-
esistant organisms  (MDROs)  are  routinely  placed
n contact  isolation,  with  en  suite  or  designated
athrooms. An  MDRO  is deﬁned  as  any  organism
hat is  resistant  to  at  least  three  drugs  within
he following  classes:  -lactams  (piperacillin,
iperacillin—tazobactam,  ceftazidime,  cefepime,
icarcillin, ticarcillin—clavulanate),  carbapen-
ms (imipenem,  meropenem),  aminoglycosides
gentamicin,  tobramycin,  amikacin)  and  ﬂu-
roquinolones  (ciproﬂoxacin,  levoﬂoxacin)
16,17].
Before the  launch  of  the  reporting  initiative,  an
ducational  program  was  delivered  to  prescribers
uring hospital  grand  rounds  and  as  additional
eminars on  antibiotic  stewardship.  The  program
ntroduced  cascade  reporting,  the  beneﬁts  and  dis-
dvantages  of  such  reporting  and  the  concept  of
estrictive  reporting  in  general.  Speciﬁc  examples
ere shared  with  prescribing  physicians  to  justify
he restrictions.  These  examples  included  the  rea-
ons for  removing  amikacin,  ampicillin,  cefazolin
nd cefuroxime  and  retaining  gentamicin,  ceftria-
one, ciproﬂoxacin  and  one  carbapenem  on  the
eporting  panel  for  Enterobacteriaceae.
After the  educational  program  began,  the
nfectious disease  specialist  and  microbiology  lab-
ratory technicians  experienced  increasing  calls
rom physicians  regarding  the  proposed  changes.
any physicians  were  comfortable  only  with  pre-
cribing  familiar  antibiotics.  We  were  able  to
lleviate  concerns  via  further  discussion  and  the
rovision  of  published  support  for  the  interven-
ion. In  addition,  we  held  small  group  meetings
ith the  main  in-patient  prescribers,  which  were
lso attended  by  key  and  inﬂuential  physicians.  The
hysicians  eventually  agreed  to  support  the  stew-
rdship initiative.
tatistical analyses
tatistical  analyses  were  performed  using  the
PSS statistical  software,  version  10.1  (SPSS).  Thexpressed  per  1000  patient-days  before  and  after
he intervention.  The  antibiotic  susceptibilities  of
elected organisms  were  reported  as  percentage
238  J.A.  Al-Tawﬁq  et  al.
susceptible.  The  change  in  DDD/1000  patient-days
was computed.  Differences  in  susceptibility  testing
results were  compared  using  the  Chi-square  test,
and a  P  value  of  ≤0.05  was  considered  statistically
signiﬁcant.
Results
The  numbers  of  tested  isolates  of  E.  aerogenes
were 104  and  75  in  2009  and  2010,  respectively.
The P.  mirabilis  isolate  numbers  were  168  and
116, and  the  P.  aeruginosa  isolates  were  481  and
414 in  2009  and  2010,  respectively.  The  cumula-
tive susceptibilities  to  speciﬁc  organism—antibiotic
combinations  improved  following  the  introduction
of restrictive  reporting  (Figs.  3—5).  For  E.  aero-
genes, the  susceptibility  rates  to  amikacin  and
third-generation  cephalosporins  improved  from  10%
to 100%  (P  <  0.001)  and  from  55%  to  89%  (P  =  0.0001),
respectively  (Fig.  3).  The  changes  in  the  susceptibil-
ity rates  to  cefepime  and  piperacillin—tazobactam
were  93—97%  (P  =  0.126)  and  93—91%  (P  = 0.23),
respectively (Fig.  3).  The  ampicillin  susceptibil-
ity decreased  from  30%  in  2009  to  11%  in  2010
(P =  0.0018)  for  this  organism.
For P.  mirabilis, the  susceptibility  rates  improved
for third-generation  cephalosporins  (48%  vs.  92%,
P < 0.001)  and  piperacillin—tazobactam  (10%  vs.
98%, P <  0.001),  with  little  change  for  cefepime  (96%
vs. 93%,  P  =  0.26),  ampicillin  (69%  vs.  73%,  P = 0.46)
and amikacin  (96%  vs.  84%,  P <  0.005)  (Fig.  4).
The susceptibility  rates  for  third-generation
cephalosporins  somewhat  improved  for  P.
aeruginosa (81%  vs.  91%,  P <  0.001)  (Fig.  5). How-
ever, the  susceptibility  to  piperacillin—tazobactam
signiﬁcantly  reduced  (99%  vs.  59%,  P  < 0.001),
which was  presumed  to  be  the  result  of  the  overall
Figure  3  Enterobacter  aerogenes  percentage  suscepti-
bility  rates  in  2009  (solid  bars)  and  2010  (dashed  bars).
The  numbers  of  tested  organisms  were  104  and  75  in  2009
and  2010,  respectively.
Figure  4  Proteus  mirabilis  percentage  susceptibility
rates  in  2009  and  2010.  The  numbers  tested  were  168  and
116  in  2009  (solid  bars)  and  2010  (dashed  bars),  respec-
tively.
Figure  5  Pseudomonas  aeruginosa  percentage  suscepti-
bility  rates  in  2009  and  2010.  The  numbers  tested  were
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P81  and  414  in  2009  (solid  bars)  and  2010  (dashed  bars),
espectively.
ncrease  in  the  consumption  of  this  agent  (Fig.  6).
he susceptibility  rates  for  cefepime,  levoﬂoxacin,
obramycin or  amikacin  did  not  change.
As shown  in  Fig.  6, the  uses  of  amoxi-
illin and  ampicillin,  piperacillin—tazobactam,
icarcillin—clavulanic  acid,  ceftriaxone  and
moxicillin—clavulanic  acid  increased  throughout
he hospital,  with  small  increases  for  levoﬂoxacin
nd ceftazidime.  The  utilization  rates  of  cefepime
nd amikacin  markedly  decreased,  with  smaller
ecreases  for  cefuroxime  and  cefazolin.  The  annual
. difﬁcile  rate  reduced  from  0.11  to  0.07  per
000 patient  days  in  2009  and  2010,  respectively
P <  0.001).
iscussion
he  introduction  of  selective  reporting  resulted
n a measurable  diminution  of  resistance  for
ome organism—antibiotic  combinations,  excluding
. aeruginosa. The  overall  impact  was  less  than
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Figure  6  The  percentage  change  of  DDDs/1000  patient-days  of  selected  antibiotics;  the  comparison  of  usage  before
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fnd  after  the  change  in  the  reporting  of  susceptibility  pa
hange  (June  2010—December  2010).
oped,  and  prescribers  are  assumed  to  not  neces-
arily  support  the  policy  for  all  patients.  Clinical
nstances in  which  patients  required  treatment  with
 restricted  agent  due  to  extreme-drug  resistance
re also  suspected.  In  addition,  the  increased  use
f one  member  of  an  antibiotic  class  will  select  for
esistance  to  other  members  of  the  same  class  as
ell as  for  unrelated  agents.  This  selection  may
xplain  the  differences  in  resistance  rates  between
he three  species  of  organisms  studied.  The  uni-
ersal  restriction  of  amikacin  and  cefepime  has
een noted  to  signiﬁcantly  reduce  consumption,
ut increased  susceptibility  was  not  universally
emonstrated  among  the  organisms  studied.  Once
n organism  gains  resistance,  it  apparently  is  not
asily lost  [2].  Continuous  antibiotic  exposure,  even
o agents  belonging  to  unrelated  classes,  will  main-
ain a  certain  level  of  resistance  in  a  conﬁned  area,
uch as  a hospital.
Despite  the  absence  of  any  identiﬁed  outbreaks
uring the  study,  the  restricted  reporting  initia-
ive is  potentially  confounded  by  infection  control
eﬁcits,  e.g.,  infection  clusters,  localized  infec-
ion control  problems,  the  role  of  carriers,  etc.  The
and hygiene  rate  increased  from  40%  to  85%  in
004 and  2011,  respectively  [18]. Device-associated
nfection prevention  bundles  were  introduced  in
006 for  ventilator-associated  pneumonia  (VAP),
n 2008  for  central  line-associated  blood  stream
nfections (CLABSI)  and  in  mid-2010  for  catheter-
ssociated urinary  tract  infections  (CAUTI)  [19].
t
r
p
c (December  2009—May  2010)  compared  to  that  after  the
he  latter  intervention  may  have  impacted  the
tudy reported  here.
Selective  and/or  cascade  reporting  allows  the
icrobiology  laboratory  to  take  a more  active  role
n antimicrobial  stewardship  [20].  In  this  study,
e used  a modiﬁed  approach  to  cascade  repor-
ing by  releasing  not  the  least  expensive  but
he most  effective  drug  based  on  the  antibi-
gram. In  a  survey  of  selective  reporting  for
rinary tract  infections,  this  technique  improved
he appropriateness  of  antibiotic  prescriptions  from
% to  14%  [21].  As  anticipated,  the  routine  repor-
ing of  ampicillin,  ticarcillin—clavulanic  acid  and
iperacillin—tazobactam  resulted  in  increased  con-
umption.  A  previous  study  showed  that  the  routine
eporting  of rifampicin  susceptibility  increased
he use  of  rifampicin  [22]. The  hospital  turnover
ncreased markedly  during  the  study,  and  our
ttempts  to  curtail  piperacillin/tazobactam  were
nsuccessful.  Clinicians  were  predisposed  to  select
his agent  because  cephalosporins  and  amikacin
ere also  restricted.  We  believe  that  without  the
tudy, the  consumption  of  piperacillin—tazobactam
ould  have  reached  a much  greater  level,  given  the
rend witnessed  previously  at  our  hospital.  In  addi-
ion, piperacillin—tazobactam  was  being  released
or use  in  patients  with  serious  pseudomonal  infec-
ions.  The  antibiotics  considered  for  selective
eporting should  reﬂect  clinical  need,  the  local
revalence  of  resistance,  approved  indications  and
linical guidelines  [23].  While  selective  reporting
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alters  the  prescribing  rates  of  different  antibiotics,
the strategy  may  not  necessarily  be  associated
with a  better  choice  of  antibiotic  therapy  [24].  E.
aerogenes  is  naturally  ampicillin  resistant  due  to
a chromosomal  AmpC  beta-lactamase.  Therefore,
the reported  change  in  susceptibility  from  30%  to
10% may  be  attributed  to  other  factors,  such  as
varying  AmpC  expression.  The  literature  and  guide-
lines (e.g.,  EUCAST  Expert  Rules)  discourages  the
use of  third-generation  cephalosporins  for  E.  aero-
genes [25].  The  reason  for  this  is the  induction
of the  chromosomal  AmpC  and  selection  of  con-
stitutively overexpressing  mutants.  Thus,  ﬁnding
that abandoning  the  use  of  cefepime  inﬂuenced
third-generation  cephalosporin  susceptibility  can
be anticipated  on  this  basis.
In conclusion,  the  restrictive  reporting  of  antibi-
otic susceptibilities  for  key  pathogens  inﬂuenced
clinical prescribing  and  permitted  a  laboratory-
based contribution  toward  an  antimicrobial  stew-
ardship  program.  Some  notable  improvements  in
the susceptibility  rates  for  selected  Enterobacteri-
aceae were  observed,  and  the  increased  awareness
of prudent  prescribing  may  have  also  contributed
to a  decreased  rate  of  C.  difﬁcile  infection.  Pre-
dicting  further  long-term  beneﬁts  on  resistance
rates from  this  type  of  study  is  difﬁcult,  but
the current  concern  for  increasing  resistance  jus-
tiﬁes an  attempt  to  improve  the  local  use  of
antibiotics.
We would  have  preferred  to  collect  data  on
all hospital  pathogens  isolated  in  the  microbiology
laboratory but  lacked  the  resources  to  do  so.  We
decided  to  focus  on  the  most  common  pathogens
isolated in  our  laboratory,  particularly  those  that
showed the  highest  rates  of  resistance.  We  could
not remove  imipenem  from  routine  reporting,  as
clinicians  were  adamant  about  availability;  it  was
also needed  for  pan-resistant  isolates,  but  the  edu-
cational  component  of  the  program  highlighted
the adverse  effects  resulting  from  the  frequent
use of  this  drug.  The  study  was  supported  by
ward-based pharmacists  who  identiﬁed  patients
that received  restricted  or  broad-spectrum  agents,
including  imipenem,  and  approached  clinicians  who
aimed to  stop  or  change  prescribed  drugs  to  a
less powerful  agent.  Ongoing  support  is  required
for prescribers  whenever  an  antibiotic  stewardship
initiative is  implemented.  Clinicians  should  be  pro-
vided with  advice  at  all  stages  of  any  intervention,
including ward  visits,  seminars,  telephone  teaching
and after-hours  discussion.  Repeated  educational
or policy  methods  and  the  implementation  of  such
activities  in  future  studies  would  increase  support
among  healthcare  personnel.  Similarly,  having  an
educational  and  initial  teaching  for  undergraduate
(
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edical  students,  who  are  the  prescribing  doctors
f the  future,  is  important  [26].
The  limitations  of  the  current  study  include  the
ollowing:  difﬁculties  in  persuading  colleagues  to
rescribe speciﬁc  agents  or  combinations  of  agents,
elevant  microbiology  not  always  sent,  laboratory
reak points  not  necessarily  reﬂecting  the  clinical
ituation,  no  incentive  for  prescribers  to  choose
ore  appropriate  antibiotics  and  the  reduced  con-
umption of  one  antibiotic  class  leading  to  the
ncreased  consumption  of  another,  which  will  also
nﬂuence  antimicrobial  susceptibilities  in  the  hospi-
al. Antimicrobial  selection  pressures  are  expected
o constantly  undermine  the  stewardship  initiative.
egarding  the  strengths  of  this  study,  it  represented
n opportunity  for  the  microbiology  laboratory  and
ts staff  not  only  to  highlight  the  importance  of
ncreasing  antimicrobial  resistance  to  clinicians  but
lso to  implement  a  strategy  to  tackle  this  resis-
ance.  The  study  also  forged  relationships  between
linicians  and  microbiologists  and  provided  a focus
n antimicrobial  resistance  for  the  hospital,  with
urther  opportunities  to  implement  stewardship  ini-
iatives.
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